Jubilant Pharmova Limited announced on Saturday (September 20) that the United States Food and Drug Administration (USFDA) successfully completed a Post-marketing Adverse Drug Experience (PADE) inspection of Jubilant Cadista Pharmaceuticals Inc, USA, a subsidiary of its wholly owned arm, Jubilant Pharma Limited.
The inspection, held on September 19, 2025, concluded with zero observations, a significant validation of the company’s adherence to stringent global quality and safety standards.
The company said this outcome reflects its commitment to maintaining the highest levels of compliance across its operations.
Jubilant Pharmova, formerly Jubilant Life Sciences, operates globally with businesses spanning Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics, and Proprietary Novel Drugs. Its Radiopharma unit, for instance, manages a strong network of 45 radiopharmacies across the US.
Q1 FY26 Results
On July 29, Jubilant Pharmova reported a decline in first-quarter profit owing to a high base last year. However, the company posted strong operational growth across its businesses.
Revenue rose 9.2% year-on-year to ₹1,901 crore from ₹1,732 crore, led by improved performance in CRDMO, sterile injectables, and generics. EBITDA grew 14% to ₹302 crore, with margins improving to 15.3% from 14.5% a year ago, highlighting efficiency gains and robust execution.
